[go: up one dir, main page]

EP0906025A4 - Produits laitiers - Google Patents

Produits laitiers

Info

Publication number
EP0906025A4
EP0906025A4 EP97903579A EP97903579A EP0906025A4 EP 0906025 A4 EP0906025 A4 EP 0906025A4 EP 97903579 A EP97903579 A EP 97903579A EP 97903579 A EP97903579 A EP 97903579A EP 0906025 A4 EP0906025 A4 EP 0906025A4
Authority
EP
European Patent Office
Prior art keywords
vit
methionine
folic acid
hcy
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97903579A
Other languages
German (de)
English (en)
Other versions
EP0906025A1 (fr
Inventor
Niva Shapira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0906025A1 publication Critical patent/EP0906025A1/fr
Publication of EP0906025A4 publication Critical patent/EP0906025A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/09—Other cheese preparations; Mixtures of cheese with other foodstuffs
    • A23C19/0921—Addition, to cheese or curd, of minerals, including organic salts thereof, trace elements, amino acids, peptides, protein hydrolysates, nucleic acids, yeast extracts or autolysate, vitamins or derivatives of these compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C13/00—Cream; Cream preparations; Making thereof
    • A23C13/12—Cream preparations
    • A23C13/16—Cream preparations containing, or treated with, microorganisms, enzymes, or antibiotics; Sour cream
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/56—Liquid products; Solid products in the form of powders, flakes or granules for making liquid products, e.g. for making chocolate milk, drinks and the products for their preparation, pastes for spreading or milk crumb
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G2200/00—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
    • A23G2200/04—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents containing vitamins, antibiotics, other medicaments

Definitions

  • the present invention relates to low homocysteinogenic dairy products enriched with Vit B6 and optionally with folic acid, magnesium, cysteine and Vit B12.
  • hyperhomocysteinemia is associated also with other health and mental risks, e.g. high homocysteine (HCY) and manic depressions, seizure disorders, depression, asthma and migraine headaches. All said diseases respond extremely well to Vit B6 therapy. (Braverman and Pfeiffer, 1987, In: The Healing nutrients within, D. Homocysteine, p. 155-162, Keats Pub ⁇ lish.Inc.New Canaan, Conn.). This can be done due to the fact that HCY is a most exicatory amino acid. Representative reports regarding recent research evidence on the mental implications of hyper-HCY and/or interrupted sulfur-amino acid metabolism ' are in particular presented in the following articles:
  • HCY or tHCY in connection with the present invention refer to the sum of the multiple forms of homocysteine, homocystine and cysteine-homocysteine complex.
  • HCY levels on vascular diseases appeared to be independent from LDL or HDL, diabetes mellitus, smoking body mass index, high blood pressure and age.
  • the LDL is the high cholesterol and high risk fraction in the human plasma.
  • HDL is the protective lipoprotein fraction.
  • hyperhomocysteinemia is an independent risk factor although some correlations exist between HCY with other risk factors, i.e. between HCY and advanced age, reduced physical activity, increased smoking, higher cholesterol levels and increased diastolic pressure. (Nygard et. al. , 1995, JAMA, 274(19:1526- 33) .
  • HCY levels were associated with an increased risk of arteriosclerotic vascular diseases. This association meets the criteria of causality (111 AB, 1965, Proc. R. Soc. Med. 58:295- 300), consistency, strength, temporality and biological plausibility. Elevated t-HCY levels precede the occurrence of coronary heart diseases. (Stampler et. al. , 1992, JAMA268:877- 881). Early signs of premature carotid arterial stenosis were found by ultrasound among heterozygoses for homocysteinuria. (Rubbet. al. 1990, Metabolism 1191-1195; Clarke et. al., 1992, " Ir. J. Med. Sci.
  • a ther olabile variant of methylene tetrahydro folate reductase can explain about 17% of CVD patients and 28% of patients suffering of a premature vascular disease who had hyperhomocysteinemia.
  • the latter condition can be treated by administering folic acid (Kang et. al. , 1988, Am. Hum. Genet. 43:414-421) .
  • hyperhomocysteinemia may result primarily from diet due to either high intake of methionine or inadequate intake of the cofactor ⁇ Vit B6, folic acid, magnesium, cysteine and/or Vit B12 which are involved in converting HCY into methionine or degradation of HCY to keto-butyrate.
  • condition ⁇ namely high methionine and low Vit B6 and/or other cofactors can exist in animal protein, i.e. in dairy products.
  • Homocysteine is a natural amino acid metabolite of the methionine, but it occurs only transiently before being converted into the harmles ⁇ cystathionine by (Cystathionine synthase) . Cystathionine is then cleaved to form cysteine, 2- ketobutyrate and ammonium ions (by cystathioninase) . Both enzymes involved comprise pyridoxal (Vit B6) phosphate as coenzyme.
  • Vit B6 pyridoxine
  • folic acid has been found to be most effective in reducing fasting HCY (Brattstrom et. al., 1990, Athero ⁇ clerosi ⁇ , 81:51-60; Bratt ⁇ trom et. al., 1992, A. Neural. Re ⁇ ., 14:81).
  • the addition of Vit B6 did not prevent high fasting plasma HCY in adults but it reduced the HCY levels in fast growing rats when the requirements of HCY were increased (Coburn, 1990, Ann. N.Y. Acad. Sci., 585:76-85) as well as under methionine load (Miller et.
  • Hyperhomo- cysteinemiacysteinemia was defined by two alternative measures, namely high fasting level and/or after oral methionine loading. Bother showed to be independent risk factors for CVD (Bo ⁇ tom et. al. , Artherosclerosis, 116:147-51). The authors found that 75% of tho ⁇ e with post- ethionine loading hperHCY had fasting total HCY concentrations below the 75th percentile (10.7 mcmole/1). They therefore concluded that fasting total plasma HCY determination alone fails to identify a sizable percentage, more than 40% of persons who have clinically relevant hyperhomocysteinemia post methionine loading. This empha ⁇ ize ⁇ the importance of Vit B6 coming together with high methionine food ⁇ . Folic acid can reduce HCY by re-mythlation and thus produce methionine. Thus this step seems to be less effective under methionine load.
  • Vit B6 deficiency can block the pathway of HCY catabolism to cysteine and thu ⁇ reduce the availability of cysteine. Accumulated aggregates of HCY with cysteine to form mixed disulfide ⁇ can further lead to secondary cysteine deficiency, that can effect the glutathione antioxidative system, which is important for cardio-vascular health. Diets high in meat and dairy products, which comprise a large amount of methionine, require more Vit. B6, but often cont :.n less B6 due to losse ⁇ during food processing (Papaioannou, 1986, Medical Hypothesis, cited in Braverman and Pfeiffer al., 1987).
  • Homocysteine increase ⁇ a ⁇ folic acid decrease ⁇ in pla ⁇ ma of healthy men during ⁇ hort term dietary folic acid and methyl group re ⁇ triction Jacob et. al. , J. Nutr. 1994, 124(7) :1072- 80.
  • the po ⁇ ible a ⁇ ociation of folic acid deficiency with homocy ⁇ teinemia was recently investigated. (Kang et. al. , 1987, Metabolism 36; 458-462; Stabler, et. al. , 1988, J. Clin. Invest. 81:466-74). They demonstrated a striking negative correlation between serum folic acid concentrations and protein-bound HCY.
  • Folic acid appears to be the mo ⁇ t effective agent again ⁇ t hyperHCY as it reduced fasting levels even when given alone.
  • Low folic acid status is mo ⁇ t commonly caused by low dietary folic intake (Stampfer, et. al. , 1995, N. Eng. J. Med., 332:328-329) .
  • the folic acid-Vit B12 required re-methylation of homocysteine to methionine normally converts " 50% of available homocysteine back to methionine.
  • thi ⁇ ⁇ tep i ⁇ inhibited either due to Vit B12 deficiency or inborn fault ⁇ of Vit 12 metabolism or folic acid metabolism, it was shown to elevate the concentration of circulating homocysteine to values thought to represent an important risk factor for the development of occlusive vascular disease (Baum-gartner , et. al., 1980, J. Inherited Metab. Dis. :101-103; Kang, et. al., 1986, U. Clin. Invest 77:1482-1486.) VIT B12;
  • Vit B12 alone i ⁇ effective in lowering HCY level ⁇ in cases with overt cobalamine deficiency (Brattstrom et. al., 1990, Atherosclerosi ⁇ , 81:51-60; Bratt ⁇ trom et. al. , 1988, Metabolism, 37:175-178; Lindenbaum et. al. , 1988, N. Eng. J. Med. 818:1720-1729).
  • Vit B12 deficiency in ⁇ heep cau ⁇ ed lipid accumulation, peroxidation and decreased liver Vit E (Kennedy et. al. 1994, Int. J. Vitam. Nutr. Re ⁇ ., 64(4) :270- 6).
  • Thi ⁇ re ⁇ ults suggest that the initiation of peroxidation is related to the increase in plasma homocysteine.
  • SAM S-adenosyl- methionine
  • ATP adenosyl-triphosphate
  • Dairy products are among the foods highest in methionine/VIT B6 ratio in low fat Ricotta, for example, the ratio methionine/ Vit B6 is 14245:1 (mg/mg). In many beef varieties it is around 2000 and in many cereals it is around 500.
  • the RDA' (recom- mended daily allowance) 1 cup (226 g) of low fat cottage cheese 2% contains 934 mg of methionine, which corresponds about to 200% of the RDA but only 0.172 mg of vit B6 which is 8.6% of the RDA. In this case the ratio methionine:Vit B6 i ⁇ 5430.
  • the concentrations of folic acid and magne ⁇ ium are proportionally quite low, i.e. one cup of low fat 2% cottage chee ⁇ e contains 16% and 4% of the RDA for folic acid and magnesium, re ⁇ pectively.
  • the methionine concentration (as % of RDA) i ⁇ 20, 13, and 50 ti e ⁇ higher than that of the above metabolic cofactor ⁇ ,re ⁇ pectively.
  • Human milk has a much higher whey : casein ratio than cows milk. Increasing the ratio of the Whey fraction is the basic step for converting cows milk ingredients into humanized infant milk formula.
  • Vit B6 is water-soluble. It is very sen ⁇ itive. Proce ⁇ ing can result in considerable lo ⁇ s of its activity: 15 to 70% in freezing fruits and vegetables; 50% to 70% in processing meats, 50% to 90% in milling grain.
  • FOLIC ACID
  • Vit B12 i ⁇ relatively ⁇ table in heat and light. It is stored to some degree in liver, kidney, lungs and spleen. Thu ⁇ , it can be balanced easier, and not all the required amount has to be eaten every day.
  • a further advantage of human milk resides in the fact that it comprises a larger amount of cysteine.
  • cysteine is a very crucial amino acid involved in the production of glutathione, which is a main factor in the detoxification and antioxidative systems.
  • Glutathione a cysteine-containing tripeptide, i ⁇ the most abundant non- protein thiol in mammal cell ⁇ . Glutathione play ⁇ an important role in the detoxification of xenobiotic compounds and in the antioxidation of reactive oxygen species and free radicals.
  • the present invention thu ⁇ con ⁇ i ⁇ ts in a dairy product in which the ratio methionine:Vit B6 (mg/mg) i ⁇ 100 - 1400 : l, preferably 300 - 600 : l, advantageously 340 - 400 : l. Said ratio may also be calculated on the basis of methio- nine/protein : Vit B6 (the term methionine/protein (met/prot) defines how much methionine i ⁇ part of the protein pre ⁇ ent) a ⁇ follows:0.017-0.024(methionine/protein)340-550 1 (methionine/
  • the ratio may also be calculated on the ba ⁇ is of the RDA.
  • the methionine contributes 200% of the RDA in order to attain 25% of the methionine the Vit B6 will increase to 50% of its own RDA.
  • the preferred range is between 35-60% RDA of Vit B6/RDA of methionine.
  • the present invention also consi ⁇ t ⁇ in dairy product ⁇ which in addition to an increa ⁇ ed amount of Vit B6 compri ⁇ e increased compounds of one or more of the following cofactors:
  • the ratio methionine : folic (mg/mg) acid should be 3000 - 8500: 1. It is preferably 3000 - 6500 :1,advantageously 3500- ' 5000: l.
  • the recommended ratios are, according to the concentration of the methionine in the protein:
  • the ratio methionine : magne ⁇ ium (mg/mg) should be 1.0 - 7.4 : l, preferably 1.5 - 5.5 : 1 advantageou ⁇ ly 2.0 - 3.7 : 1.
  • the recommended ratio ⁇ are, according to the concentration of methionine in the protein:
  • the ratio methionine : cy ⁇ teine(mg/mg) should be0.5-5.5:l preferably 1.5 - 3.8 : 1, advantageou ⁇ ly 2.0 - 2.8. : 1.
  • the recommended ratio ⁇ are, according to the concentration of the methionine in the product:
  • the ratio methionine :Vit B12(mg/mcg) ⁇ hould be77 -600 : 1, preferably 100 - 470 : 1, advantageou ⁇ ly 120 - 280 : 1.
  • the present invention will now be illustrated with reference to the following exa ple ⁇ without being limited by them.
  • the example ⁇ pre ⁇ ent the suggested concentrations of Vitamins B6 and B12, folic acid, magnesium and cysteine.
  • the marked figures represent firstly the original/endogenic concentration and then a final representative concentration.
  • the amount ⁇ to be added are complementary to the original concentration ⁇ . Thu ⁇ , the added amount will be calculated by ⁇ ubtraction of the original content from the final de ⁇ ired value.
  • the percentages represent the values a ⁇ % of the Israeli RDA for adult males (50-70).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Produits laitiers peu homocystéinogènes enrichis en vitamine B6 et, éventuellement, en acide folique, vitamine B12 et magnésium. Produits laitiers contenant des proportions spécifiques de méthionine, cystéine, vitamine B6, acide folique, vitamine B12 et magnésium.
EP97903579A 1996-03-15 1997-03-05 Produits laitiers Withdrawn EP0906025A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11750596A IL117505A (en) 1996-03-15 1996-03-15 Enriched dairy products
IL11750596 1996-03-15
PCT/IL1997/000080 WO1997034497A1 (fr) 1996-03-15 1997-03-05 Produits laitiers

Publications (2)

Publication Number Publication Date
EP0906025A1 EP0906025A1 (fr) 1999-04-07
EP0906025A4 true EP0906025A4 (fr) 1999-11-17

Family

ID=11068667

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97903579A Withdrawn EP0906025A4 (fr) 1996-03-15 1997-03-05 Produits laitiers

Country Status (4)

Country Link
EP (1) EP0906025A4 (fr)
AU (1) AU1809997A (fr)
IL (1) IL117505A (fr)
WO (1) WO1997034497A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771754B2 (en) * 1999-06-29 2004-04-01 New Zealand Milk Institute Limited, The Prophylactic dietary supplement based on milk
ES2260500T3 (es) * 2001-12-21 2006-11-01 Dsm Ip Assets B.V. Productos alimenticios ricos en mentionina modificados y procesos para su fabricacion.

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797298A (en) * 1955-02-02 1958-07-02 White Lab Inc Prepared milk for infants in substandard nutritional state
GB993719A (en) * 1961-06-28 1965-06-02 Nestle Sa Infants' milk powder
FR1583482A (fr) * 1968-08-09 1969-10-31
DE1948378A1 (de) * 1969-09-24 1971-04-01 Rolf Dr Schuler Verfahren zur Herstellung vitaminierter Milcherzeugnisse
US4237118A (en) * 1972-03-06 1980-12-02 Howard Alan N Dietary supplement and dietary methods employing said supplement for the treatment of obesity
EP0129418A2 (fr) * 1983-06-16 1984-12-27 Farley Health Products Limited Produit alimentaire infantile
FR2676890A1 (fr) * 1991-05-30 1992-12-04 Grillot Brevet Freres Ets Paul Procede pour la fabrication d'un fromage hyposode, enrichi en magnesium.
WO1994005159A2 (fr) * 1992-09-10 1994-03-17 La Societe Cooperative Mont-Blanc Boisson lactee enrichie de nutriments
US5447741A (en) * 1994-04-05 1995-09-05 Goldman; Marc S. Milk composition containing fiber and method for making same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871550A (en) * 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
FI892006A7 (fi) * 1988-04-29 1989-10-30 Phil Gold Laktalbumiini ruoan lisäaineena

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797298A (en) * 1955-02-02 1958-07-02 White Lab Inc Prepared milk for infants in substandard nutritional state
GB993719A (en) * 1961-06-28 1965-06-02 Nestle Sa Infants' milk powder
FR1583482A (fr) * 1968-08-09 1969-10-31
DE1948378A1 (de) * 1969-09-24 1971-04-01 Rolf Dr Schuler Verfahren zur Herstellung vitaminierter Milcherzeugnisse
US4237118A (en) * 1972-03-06 1980-12-02 Howard Alan N Dietary supplement and dietary methods employing said supplement for the treatment of obesity
EP0129418A2 (fr) * 1983-06-16 1984-12-27 Farley Health Products Limited Produit alimentaire infantile
FR2676890A1 (fr) * 1991-05-30 1992-12-04 Grillot Brevet Freres Ets Paul Procede pour la fabrication d'un fromage hyposode, enrichi en magnesium.
WO1994005159A2 (fr) * 1992-09-10 1994-03-17 La Societe Cooperative Mont-Blanc Boisson lactee enrichie de nutriments
US5447741A (en) * 1994-04-05 1995-09-05 Goldman; Marc S. Milk composition containing fiber and method for making same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B. FUSSNEGGER: "Vitamine und Provitamine: Ihre Stabilität in Milch und Milchprodukten", DEUTSCHE MOLKEREI ZEITUNG DMZ, vol. 109, no. 17, 1988, MUNCHEN DE, pages 514 - 518, XP002115298 *
See also references of WO9734497A1 *

Also Published As

Publication number Publication date
EP0906025A1 (fr) 1999-04-07
WO1997034497A1 (fr) 1997-09-25
IL117505A (en) 1999-09-22
AU1809997A (en) 1997-10-10
IL117505A0 (en) 1996-07-23

Similar Documents

Publication Publication Date Title
Hepner et al. Hypocholesterolemic effect of yogurt and milk
Miller et al. Handbook of dairy foods and nutrition
US6503545B1 (en) Hyper-absorption of vitamin E combined with milk protein
Gibson et al. Nutrition intervention strategies to combat zinc deficiency in developing countries
Carroll et al. Hypocholesterolemic effect of substituting soybean protein for animal protein in the diet of healthy young women
van Meijl et al. Dairy product consumption and the metabolic syndrome
Jaspers et al. Effect of consuming yogurts prepared with three culture strains on human serum lipoproteins
JP5537438B2 (ja) 卵黄に基づく機能性食物製品の生産方法およびこれによって得られる製品
Kahraman et al. Effect of zinc fortification on Cheddar cheese quality
US7790670B2 (en) Compositions and methods for treatment of body weight conditions
KR19990087376A (ko) 식품 보충제 또는 혈청 지질 감소용 조성물 및 그의 용도
Aljaadi et al. Riboflavin intake and status and relationship to anemia
JP2004537302A (ja) 栄養価を高めた米糠食品および心臓血管系健康の促進方法
Tiwari et al. Nutritional Values and Therapeutic Uses of Capra hircus Milk.
US5993866A (en) Process of making food products having reduced methionine ratios
HAMBIDGE Trace elements in pediatric nutrition
Khan-Siddiqui et al. Plasma carnitine levels in adult males in India: effects of high cereal, low fat diet, fat supplementation, and nutrition status
WO1997034497A1 (fr) Produits laitiers
Johnston et al. Folate content of dairy products measured by microbiological assay with trienzyme treatment
Ortega et al. The consumption of milk products in a group of pre-school children: influence on serum lipid profile
EP1255448B1 (fr) Aliment additionne de carnitine capable de stimuler la biosynthese d'acides gras polyinsatures a partir des acides gras satures contenus dans cet aliment
Frąckiewicz The nutritional and health value of milk and fermented milk drinks®
Pearce Effects of milk and fermented dairy products on the blood cholesterol content and profile of mammals in relation to coronary heart disease
Borsook The relation of the vitamin B6 human requirement to the amount in the diet
Brink et al. Urinary excretion of magnesium and calcium as an index of absorption is not affected by lactose intake in healthy adults

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE DE DK FR GB IT NL SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 6A 23C 9/00 A, 6A 23C 9/158 B, 6A 23C 9/13 B, 6A 23C 19/09 B, 6A 23C 9/152 B

A4 Supplementary search report drawn up and despatched

Effective date: 19991005

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE DE DK FR GB IT NL SE

17Q First examination report despatched

Effective date: 20020823

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041129